Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Retinal Vein Thrombosis Clear all
Not listed Phase 4 Interventional

Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy

NCT01857544
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Aflibercept
Drug
Lead sponsor
Tennessee Retina
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Jul 23, 2026, 11:28 AM EDT
Terminated No phase listed Observational

Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)

NCT01875770
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Jul 23, 2026, 11:28 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion

NCT04740905
View directory record Official record
Conditions
Macular Edema, Branch Retinal Vein Occlusion
Interventions
Faricimab, Aflibercept, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
39
States / cities
Phoenix, Arizona • Tucson, Arizona • Campbell, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Jul 23, 2026, 11:28 AM EDT
Completed Phase 4 Interventional

NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions

NCT01870427
View directory record Official record
Conditions
Macular Edema With Central Retinal Vein Occlusions
Interventions
Aflibercept (2.0 mg)
Drug
Lead sponsor
Northern California Retina Vitreous Associates
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Jul 23, 2026, 11:28 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion

NCT00168324
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
700 µg Dexamethasone, 350 µg Dexamethasone, Sham Injection
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Jul 23, 2026, 11:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Minocycline to Treat Branch Retinal Vein Occlusion

NCT01468831
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Minocycline, Placebo, Bevacizumab
Drug · Other
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Jul 23, 2026, 11:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Intravitreal Injection Site and Perceived Pain

NCT05640895
View directory record Official record
Conditions
Pain
Interventions
Intravitreal injection site
Procedure
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 100 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Jul 23, 2026, 11:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)

NCT01027650
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
AGN208397 intravitreal injection, dexamethasone intravitreal implant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Jul 23, 2026, 11:28 AM EDT
Not listed Not applicable Interventional

Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion

NCT01581151
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Dexamethasone intravitreal implant, Monthly Ranibizumab
Drug
Lead sponsor
Brian Burke, MPH
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2015 · Synced Jul 23, 2026, 11:28 AM EDT
Completed Phase 4 Interventional Results available

Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO

NCT02503540
View directory record Official record
Conditions
Retinal Vein Occlusion, Diabetic Macular Edema, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion
Interventions
Aflibercept
Drug
Lead sponsor
Justis Ehlers
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Jul 23, 2026, 11:28 AM EDT
Terminated Phase 3 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

NCT02980874
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
suprachoroidal CLS-TA, suprachoroidal sham, IVT aflibercept
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
58
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Jul 23, 2026, 11:28 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema

NCT02867735
View directory record Official record
Conditions
Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusions
Interventions
LKA651, Sham Comparator
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Pasadena, California • Fort Myers, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Jul 23, 2026, 11:28 AM EDT
Terminated Not applicable Interventional Results available

SD-OCT Angiography

NCT02510885
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Age-related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
AngioVue SD-OCT
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Jul 23, 2026, 11:28 AM EDT
Completed Not applicable Interventional Results available

A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion

NCT00952614
View directory record Official record
Conditions
Central Retinal Vein Occlusion
Interventions
fluocinolone acetonide (Retisert Implant, Bausch and Lomb)
Device
Lead sponsor
Glenn Jaffe
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 5, 2014 · Synced Jul 23, 2026, 11:28 AM EDT
Terminated Phase 1 Interventional

Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO

NCT03790852
View directory record Official record
Conditions
Wet Age-related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
KSI-301
Drug
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
21 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Beverly Hills, California • Mountain View, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Jul 23, 2026, 11:28 AM EDT
Completed Phase 1Phase 2 Interventional

Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion

NCT01724554
View directory record Official record
Conditions
Central Retinal Vein Occlusion, Proliferative Diabetic Retinopathy
Interventions
Intravitreal Aflibercept Injection
Drug
Lead sponsor
Ophthalmic Consultants of Boston
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Jul 23, 2026, 11:28 AM EDT
Completed No phase listed Observational

Resistance to Antibiotics in Patients Receiving Eye Injections

NCT02126423
View directory record Official record
Conditions
Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Retinopathy
Interventions
Conjunctival and nasopharyngeal swabs
Other
Lead sponsor
Prism Vision Group
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated May 31, 2016 · Synced Jul 23, 2026, 11:28 AM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion

NCT01277302
View directory record Official record
Conditions
Macular Edema
Interventions
Ranibizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
42
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2014 · Synced Jul 23, 2026, 11:28 AM EDT
Completed Phase 4 Interventional

Ocular Safety and Usability Study for FYB203 PFS

NCT06708637
View directory record Official record
Conditions
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema, Diabetic Macular Edema, Diabetic Retinopathy
Interventions
FYB203 2 mg (0.05 mL of 40 mg/mL)
Drug
Lead sponsor
Formycon AG
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
4
States / cities
Campbell, California • Long Beach, California • Redlands, California + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Jul 23, 2026, 11:28 AM EDT
Completed Phase 2 Interventional

Research Study in Patients With Persistent Macular Edema

NCT00035906
View directory record Official record
Conditions
Diabetes, Macular Edema, Diabetic Retinopathy, Retinal Disease, Uveitis, Posterior
Interventions
DEX PS DDS®
Drug
Lead sponsor
Allergan
Industry
Eligibility
12 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated May 29, 2011 · Synced Jul 23, 2026, 11:28 AM EDT
Completed Early Phase 1 Interventional

Fluocinolone Acetonide Implant for Retinal Vein Occlusion (RVO)

NCT00636493
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
fluocinolone acetonide (Retisert Implant)
Device
Lead sponsor
Glenn Jaffe
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Jul 23, 2026, 11:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study

NCT02390245
View directory record Official record
Conditions
Glaucoma, Glaucoma Suspect, Diabetic Retinopathy, Ocular Hypertension, Cataract, Branch Retinal Vein Occlusion, Branch Retinal Arterial Occlusion, Central Retinal Vein Occlusion, Central Retinal Artery Occlusion, Epi-retinal Membrane, Macular Degeneration, Drusen, Loss of Vision
Interventions
Free Eye Screenings, Enhanced Intervention, Usual Care
Other
Lead sponsor
Wills Eye
Other
Eligibility
40 Years and older
Enrollment
906 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Jul 23, 2026, 11:28 AM EDT
Completed Not applicable Interventional Results available

Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival

NCT01640171
View directory record Official record
Conditions
Age-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
Xylocaine 2% Injectable Anesthetic, Proparacaine Hydrochloride 0.5% Drop, Tetravisc 0.5% Gel, Acuvail, Intra-vitreal Anti-VEGF Drug
Procedure · Drug
Lead sponsor
Retina Vitreous Associates of Florida
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Jul 23, 2026, 11:28 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion

NCT01827722
View directory record Official record
Conditions
Macular Edema, Central Retinal Vein Occlusion
Interventions
Ozurdex, Ranibizumab, Combination Ozurdex with Ranibizumab PRN
Drug
Lead sponsor
Valley Retina Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
5
States / cities
Beverly Hills, California • Lakeland, Florida • Winter Haven, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Jul 23, 2026, 11:28 AM EDT